Lawrence Garbo
About
Lawrence Garbo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Lawrence Garbo has authored 35 papers receiving a total of 741 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lawrence Garbo's work include Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Research Studies (8 papers) and Cancer therapeutics and mechanisms (7 papers). Lawrence Garbo is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Research Studies (8 papers) and Cancer therapeutics and mechanisms (7 papers). Lawrence Garbo collaborates with scholars based in United States, United Kingdom and Canada. Lawrence Garbo's co-authors include Donald Richards, Hedy L. Kindler, Joe Stephenson, Ellen G. Feigal, Sarah Bray, Lawrence H. Einhorn, Darren R. Feldman, Costantine Albany, Jesse McGreivy and Charles S. Fuchs and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.
In The Last Decade
Lawrence Garbo
35 papers receiving 731 citations
Peers
Lawrence Garbo
Tahir Latif United States
Karen A. Cadoo United States
Mona Fouad Egypt
Shuji Arita Japan
Robert Manges United States
Kotaro Kodama Japan
Sasja F. Mulder Netherlands
Kenichi Harano Japan
Carmen Nuzzo Italy
Chueh‐Chuan Yen Taiwan
Citations per year, relative to Lawrence Garbo Lawrence Garbo (= 1×)
peers
Tahir Latif
Countries citing papers authored by Lawrence Garbo
Since
Specialization
Citations
This map shows the geographic impact of Lawrence Garbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Garbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Garbo more than expected).
Fields of papers citing papers by Lawrence Garbo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lawrence Garbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Garbo. The network helps show where Lawrence Garbo may publish in the future.
Co-authorship network of co-authors of Lawrence Garbo
This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Garbo. A scholar is included among the top collaborators of Lawrence Garbo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Garbo. Lawrence Garbo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fakih, Marwan, Kanwal Raghav, David Chang, et al.. (2021). Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).. Journal of Clinical Oncology. 39(15_suppl). 3560–3560.
2.
Stewart, Tracy Murray, Daniel D. Von Hoff, Michael L. Fitzgerald, et al.. (2020). A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Cancer Chemotherapy and Pharmacology. 87(1). 135–144.
3.
Albany, Costantine, Lawrence H. Einhorn, Lawrence Garbo, et al.. (2017). Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. The Oncologist. 23(3). 316–323.
4.
Bahleda, Rastislav, Fadi S. Braiteh, Ani Sarkis Balmanoukian, et al.. (2017). Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results. Annals of Oncology. 28. v373–v373.
5.
Adjei, Alex A., Donald Richards, Anthony B. El-Khoueiry, et al.. (2015). A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clinical Cancer Research. 22(10). 2368–2376.
6.
Becerra, Carlos, Joe Stephenson, Derek J. Jonker, et al.. (2015). Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 33(15_suppl). 4069–4069.
7.
Jotte, Robert M., Daniel D. Von Hoff, Fadi Braiteh, et al.. (2014). An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. Investigational New Drugs. 33(1). 148–158.
8.
Kim, Edward S., Marcus A. Neubauer, Allen Lee Cohn, et al.. (2013). Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. The Lancet Oncology. 14(13). 1326–1336.
9.
Lyons, Roger M., Carole Paley, Jason Esposito, et al.. (2013). Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leukemia Research. 38(2). 149–154.
10.
Becerra, Carlos, Jeffrey R. Infante, Lawrence Garbo, et al.. (2012). A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3023–3023.
11.
Kim, Edward S., Marcus A. Neubauer, Allen Lee Cohn, et al.. (2012). SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy.. Journal of Clinical Oncology. 30(15_suppl). 7502–7502.
12.
Kindler, Hedy L., Donald Richards, Lawrence Garbo, et al.. (2012). A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of Oncology. 23(11). 2834–2842.
13.
Kindler, Hedy L., Donald Richards, John Stephenson, et al.. (2010). A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 28(15_suppl). 4035–4035.
14.
Sonpavde, Guru, Ana M. Aparicio, Feng Zhan, et al.. (2009). Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 29(6). 682–689.
15.
Sausville, E. A., et al.. (2009). A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 2574–2574.
16.
Kingsley, Edwin, et al.. (2009). An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). Journal of Clinical Oncology. 27(15_suppl). 8582–8582.
17.
Ettinger, David S., Robert M. Jotte, Paul Lorigan, et al.. (2009). Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update. Journal of Clinical Oncology. 27(15_suppl). 8103–8103.
18.
Sonpavde, Guru, Lawrence Garbo, Steven R. Rousey, et al.. (2008). Azacitidine for castration-resistant prostate cancer progressing on combined androgen blockade. Journal of Clinical Oncology. 26(15_suppl). 5172–5172.
19.
Garbo, Lawrence, et al.. (2008). Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. Investigational New Drugs. 27(5). 476–481.
20.
Sausville, Edward A., Stephen P. Anthony, Lawrence Garbo, et al.. (2007). A phase I study of the safety, tolerability, and pharmacokinetics of intravenous XMT-1001 in patients with advanced solid tumors.. 6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tahir Latif Breakdown of academic impact, for papers by Karen A. Cadoo Breakdown of academic impact, for papers by Mona Fouad Breakdown of academic impact, for papers by Shuji Arita Breakdown of academic impact, for papers by Robert Manges Breakdown of academic impact, for papers by Kotaro Kodama Breakdown of academic impact, for papers by Sasja F. Mulder Breakdown of academic impact, for papers by Kenichi Harano Breakdown of academic impact, for papers by Carmen Nuzzo Breakdown of academic impact, for papers by Chueh‐Chuan Yen